The present invention provides a protein-containing composition that can be ingested without reducing the intake, and without placing a burden on the kidney and the liver. Provided is a protein-containing composition for enteral intake, the composition including at least 81% by mass micellar casein with respect to the total protein, which composition is for ingestion by a subject requiring suppression or prevention of a decline(s) in renal function and/or liver function.

The disclosure provides novel microbial strains, such as Veillonella sp. strains, and compositions comprising the strains that are capable of converting lactate to propionate and acetate. The disclosure also provides compositions comprising the Veillonella sp. strains and lactate producing bacteria, such as Lactobacillus sp. strains and Bifidobacterium sp. strains. The disclosure further provides methods of improving athletic performance, enhancing exercise endurance and reducing inflammation in a subject upon administration of the disclosed strains or compositions.

An embodiment of the present invention relates to protein granules containing a whey protein as a main component, the protein granules having an average particle diameter of 207 μm to 570 μm, a homogeneity U of 0.58 or less, a content ratio (volume ratio) of coarse powder having a particle diameter of 500 μm or more of 22% or less, and a content ratio (volume ratio) of fine powder having a particle diameter of 150 μm or less of 31% or less.

The present disclosure relates to a pharmaceutical composition for providing phosphorus to an adult or pediatric patient, wherein the composition is an aqueous solution of sodium glycerophosphate which by virtue of an improved process for producing the active pharmaceutical ingredient and the pharmaceutical composition is characterized by a low amount of free phosphate, a low amount of SGP-related substances and by a low amount of aluminum. The pharmaceutical composition is used in clinical nutrition, preferably in the preparation of nutritional formulations by compounding. The compositions can further be used for preventing or correcting phosphorus deficiency (hyperphosphatemia) in said adult or pediatric patients.

A composition for use in a method for the treatment of an amino acid deficiency to a non-mammalian monogastric animal, such as a poultry animal, a fish or a crustacean is described, wherein said composition comprises (i) a mixture of active components comprising or, alternatively, consisting of at least one amino acid or an analogue, (ii) a lipid matrix embedding said (i) mixture of active components and, optionally, (iii) at least one acceptable pharmaceutical or food grade additive and/or excipient. Furthermore, a feed or feed additive for a non-mammalian monogastric animal, such as poultry species and/or aquatic species comprising the composition is also described.

The present disclosure provides an improvement of existing L-arginine containing supplements by providing both hydrogen crystals (H.sub.2) and co-enzyme Q10 (Co-Q10) to produce a nutrient formulation, including compositions containing said formulation and methods of administering such formulation.

The present disclosure provides an improvement of existing L-arginine containing supplements by providing both hydrogen crystals (H.sub.2) and co-enzyme Q10 (Co-Q10) to produce a nutrient formulation, including compositions containing said formulation and methods of administering such formulation.

Described herein is a method for forming multi-layer drug dosage forms having at least two layers. In the method, a first formulation comprising a non-gelling matrix forming agent and having a first density is dosed into a preformed mold. A second formulation comprising a non-gelling matrix former and having a second density not equal to the first density is subsequently dosed into the preformed mold. Then, the combination of the formulations dosed into the mold is freeze dried to form the multi-layer dosage form having at least two layers. The use of a density difference between the first and second formulations ensures formation of a product with two distinct layers.

The present invention provides a composition for improving or maintaining quality of life (QOL), comprising, as an active ingredient, a component derived from turmeric. The present invention relates to a composition for improving or maintaining QOL, comprising, as an active ingredient, at least one of turmeronol A, turmeronol B, and bisacurone. The composition of the present invention for improving or maintaining QOL may comprise 20 μg or more of turmeronol A and turmeronol B in total per daily intake, may comprise 17 μg or more of turmeronol A per daily intake, may comprise 5 μg or more of turmeronol B per daily intake, and may comprise 80 μg or more of bisacurone per daily intake.

An embodiment of the present invention relates to amino acid-containing granules containing an amino acid as a main component, the amino acid-containing granules having an average particle diameter of 150 μm to 500 μm and a homogeneity U of 0.70 or less, in which the average particle diameter and the homogeneity U are determined by the following measurement method.